Basic information Safety Related Supplier

ChemicalBook Product Catalog Biochemical Engineering Inhibitors Neuronal Signaling Adrenergic Receptor agonists Indacaterol maleate

1/1

Indacaterol maleate NEW

$30.00 10mg

$30.00 10mg

$30.00 10mg

$30.00 10mg

$48.00 25mg

$48.00 25mg

$48.00 25mg

$48.00 25mg

$68.00 50mg

$68.00 50mg

$68.00 50mg

$68.00 50mg

Min. Order
Purity99.67%
Cas No753498-25-8
Supply Ability10g
Update time2024-11-19

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

3YR

United States

show more

Chemical Properties

Product Name	Indacaterol maleate
CAS No	753498-25-8
EC-No
Min. Order
Purity	99.67%
Supply Ability	10g
Release date	2024/11/19

Product Introduction

Bioactivity

Name	Indacaterol maleate
Description	Indacaterol maleate (QAB149) is an ultra-long-acting β-adrenoceptor agonist.
In vitro	Indacaterol inhibits cAMP production in Chinese hamster ovary cells stably transfected with human β2 adrenoceptors with pEC50 of 8.06. Indacaterol inhibits electrically induced contraction on the electrically stimulated guinea pig trachea in a concentration-dependent manner with pEC50 of 8.23. Indacaterol induces a concentration-dependent inotropic effect with maximal efficacy of 75% in the isolated guinea pig left atrium. [1] Indacaterol reverses the carbachol-induced contraction in a concentration-dependent manner with IC50 of 37 nM in human small airways. Indacaterol concentration dependently reverses the serotonin-induced contraction with IC50 of 10.5 nM in rat small airways. Indacaterol has the highest intrinsic efficacy of 53% in rat small airways and 73% in human small airways. [2] Indacaterol (10 μM) induces close to full inhibition of the EFS-induced contraction of isolated human bronchi and the effect lasts 12 hours. [3] Indacaterol inhibits the IgE-dependent release of histamine from mast cells with the intrinsic activity (Emax of a long-acting Indacaterol/Emax of Isoprenaline) of 1.03. [4] Indacaterol inihbits cAMP release from human airway smooth muscle with pEC50 of 8.53 and Emax of 48%. Indacaterol appears to have a reduced efficacy compared with the CHO-K1 data in the primary ASM cells. [5]
In vivo	Indacaterol (6.7 μg/kg) inhibits 5-HT-induced bronchoconstriction with a maximal effect of 85% in the conscious guinea pig. Indacaterol (12.5 μg/kg) dose-dependently inhibits methacholine-induced bronchoconstriction with a maximal effect of 85% in the anesthetized rhesus monkey. [1]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 94 mg/mL (184.8 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble)
Keywords	Inhibitor \| NF-κB \| heart failure \| Indacaterol maleate \| myocardial infarction \| Adrenergic Receptor \| Indacaterol Maleate \| asthma \| QAB-149 \| HT1080 cells \| QAB 149 \| inhibit \| Indacaterol \| COPD \| β-arrestin2 \| Beta Receptor
Inhibitors Related	Octopamine hydrochloride \| Trazodone hydrochloride \| Mianserin hydrochloride
Related Compound Libraries	Anti-Neurodegenerative Disease Compound Library \| Bioactive Compound Library \| Membrane Protein-targeted Compound Library \| Anti-Cancer Clinical Compound Library \| FDA-Approved Drug Library \| Anti-Cancer Approved Drug Library \| Anti-Cancer Drug Library

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book